Prevention of sudden cardiac death: Management considerations

Current Opinion in Cardiology

Volumn 15, Issue 4, 2000, Pages 304-308

  Domanski, Michael J ^a  

^a Natl Heart Lung/Blood Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENCAINIDE; FLECAINIDE; METOPROLOL; MORACIZINE; SOTALOL;

CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART DEATH; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033931892     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200007000-00016     Document Type: Review

References (37)

1. 1 Engelstein E, Zipes D: Sudden cardiac death. In The Heart, Arteries, and Veins. Edited by Alexander R, Schlant R, Fuster V. New York: McGraw Hill; 1998:1081-1112.
2. 2 Myerburg R, Castellanos A: Cardiac arrest and sudden death. In Heart Disease: A Textbook of Cardiovascular Medicine. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:742-779.
3. 3 Zipes D, Wellens H: Sudden cardiac death. Circulation 1998, 2334-2351.
4. 4 Stevenson W, Stevenson L, Middlekauff H, Saxon L: Sudden death prevention in patients with advanced left ventricular dysfunction. Circulation 1993, 88:2953-2961.
5. 5 Bayes de Luna A, Cormel P, Leclerq J: Ambulatory sudden cardiac death: mechanisms of fatal arrhythmia on the basis data from 157 cases. Am Heart J 1989, 117:151-159.
6. 6 Echt D, Liebson P, Mitchell B, et al., and the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial (CAST I). N Engl J Med 1991, 321:406-412.
7. 7 The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992, 327:227-233.
8. 8 Waldo A, Camm J, deRuyter H, et al., for the SWORD Investigators: Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction (SWORD: Survival with oral d-sotalol). Lancet 1996, 348:7-12.
9. 9 Teo K, Yusuf S, Furberg C: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993, 270:1589-1595.
10. 10 Mason J, for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators: A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. N Engl M Med 1993, 329:445-451.
11. 11 Burkart F, Pfisterer M, Kiowski W, et al.: Effect of antiarrhythmic therapy on mortality on survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1992, 20:1056-1062.
12. 12 Ceremuzynski L, Kleczar K, Krzeminska-Pakula M, et al.: Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992, 20:1056-1062.
13. 13 Julian D, Camm A, Frangin G, et al., for the European Myocardial Infarction Amiodarone Trial Investigators: Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997, 349:667-674.
14. 14 Cairns J, Connolly S, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive premature depolarizations: CAMIAT. Lancet 1997, 349:675-682.
15. 15 Sim I, McDonald K, Lavoir P, Norbutas B: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997, 96:2823-2829.
16. 16 Amiodarone Trials Meta-Analysis Investigators: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997, 350:1417-1424.
17. 17 Mirowski M, Reid P, Mower M, et al.: Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989, 13:1353-1361.
18. 18 The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576-1583.
19. 19 Connolly S, Gent M, Roberts R, et al., for the CIDS Investigators: The Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000, 101:1297-1313.
20. th Annual Scientific Sessions of the American College of Cardiology, Late Breaking Clinical Trials I. March 30, 1998.
21. 21 Moss A, Hall J, Cannom D, et al., for the Multicenter Automatic Defibrillator Implantation Trial Investigators: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933-1940.
22. 22 Buxton A, Lee K, Fisher J, et al., for the Multicenter Unsustained Tachycardia Trial (MUSTT) Investigators: A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999, 341:1882-1890. Data in this study suggest that ICDs may be appropriate for coronary patients with inducible ventricular tachyarrhythmia.
23. 23 Bigger J, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators: Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997, 337:1569-1575.
24. 24 Bigger J, Whang W, Rottman J, et al.: Mechanisms of death in the CABG Patch Trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999, 99:1416-1421.
25. 25 Holmes D, Davis K, Gersh B, et al., and participants in the Coronary Artery Surgery Study: Risk factor profiles of patients with sudden death and from other cardiac causes: a report of the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1989, 13:524-530.
26. 26 Dries D, Domanski M, Waclawiw M, Gersh B: Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997, 79:909-913.
27. 27 The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981, 304:801-807.
28. 28 The Beta-Blocker Heart Attack Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: I: mortality results. JAMA 1982, 247:1707-1714.
29. 29 The Beta-Blocker Pooling Project Research Group: The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post-infarction patients. Eur Heart J 1988, 9:8-16.
30. 30 CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999, 353:9-13.
31. 31 The MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007. Along with CIBIS II, demonstrates the importance of β-blockers in patients with congestive heart failure caused by systolic dysfunction.
32. 32 Pfeffer M, Braunwald E, Moye L, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327:669-677.
33. 33 The Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
34. 34 The Studies of Left Ventricular Dysfunction Investigators: Effect of enalapril in survival in patients with reduced left ventricular ejection fraction and congestive heart failure: N Engl J Med 1991, 325:293-302.
35. 35 Kober L, Torp-Pederson C, Carlsen J, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group: A clinical trial of the ACE inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670-1676.
36. 36 Domanski M, Exner D, Borkowf C, et al.: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following a myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Card 1999, 33:598-604. The prevention of SCD is an added benefit of ACE inhibitors and such protection cannot be assumed without proof from A2 blockers.
37. 37 Pitt B, Zannad F, Remme W, et al., for the Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717. Further confirmation of therapeutic importance of antagonizing neurohormonat activation.